About this episode
Everyone’s been talking about the drug semaglutide, used to treat Type 2 diabetes. It’s marketed under the brand names Ozempic, Wegovy, and now, Mounjaro. Are any of the drugmakers a buy? Salesforce’s Successful Quarter HP is Having Problems Macy’s Misses the Mark Diabetes Drugs Take Over Biotech Frontrunners Why is Pfizer Underperforming? Semaglutide Risks Biotech Stock Picks What Higher Yields Mean for Retired ‘Bucket’ Investors Read about topics from this episode. Salesforce Earnings: Margins Shine As New Signs of Pressure Remove Some Luster HP Earnings: Sales Remain Soft, Although Improvement Is on the Horizon; Shares Fairly Valued Macy’s Earnings: Lowered Outlook on Waning Spending Overshadows Positives; Shares Undervalued Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich Obesity Drug Stocks: Time to Buy? What to watch from Morningstar. Double Trouble: How the Dot-Com and Tech Bubbles Compare What to Do as Recession Fears Grip Investors Just Where’s the U.S. Economy Headed? Active ETFs Take Off –– 3 Ideas for Investors Read what our team is writing: Ruth Saldanha Karen Andersen Susan Dziubinski Christine Benz Follow us on social media. Ruth Saldanha on Twitter: @karishmaruth Facebook: https://www.facebook.com/MorningstarInc/ Twitter: https://twitter.com/MorningstarInc Instagram: https://www.instagram.com/morningstar ... LinkedIn: https://www.linkedin.com/company/5161/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.